JP2007502301A - 腫瘍細胞の増殖を阻害するための方法 - Google Patents

腫瘍細胞の増殖を阻害するための方法 Download PDF

Info

Publication number
JP2007502301A
JP2007502301A JP2006523413A JP2006523413A JP2007502301A JP 2007502301 A JP2007502301 A JP 2007502301A JP 2006523413 A JP2006523413 A JP 2006523413A JP 2006523413 A JP2006523413 A JP 2006523413A JP 2007502301 A JP2007502301 A JP 2007502301A
Authority
JP
Japan
Prior art keywords
cell
stat3
platinum
cells
isscpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502301A5 (https=
Inventor
ジェイムズ ツルクソン
リチャード ホベ
ジェイ ダブリュー． パーマー
ハイディー カイ
ユ ホワ
Original Assignee
ユニバーシティー オブ サウス フロリダ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ サウス フロリダ filed Critical ユニバーシティー オブ サウス フロリダ
Publication of JP2007502301A publication Critical patent/JP2007502301A/ja
Publication of JP2007502301A5 publication Critical patent/JP2007502301A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2006523413A 2003-08-13 2004-08-13 腫瘍細胞の増殖を阻害するための方法 Pending JP2007502301A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48122603P 2003-08-13 2003-08-13
US51558003P 2003-10-30 2003-10-30
US51994303P 2003-11-14 2003-11-14
US52529503P 2003-11-25 2003-11-25
PCT/US2004/026392 WO2005023824A2 (en) 2003-08-13 2004-08-13 Methods for inhibiting tumor cell proliferation

Publications (2)

Publication Number Publication Date
JP2007502301A true JP2007502301A (ja) 2007-02-08
JP2007502301A5 JP2007502301A5 (https=) 2007-09-27

Family

ID=34199238

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006523413A Pending JP2007502301A (ja) 2003-08-13 2004-08-13 腫瘍細胞の増殖を阻害するための方法
JP2006523414A Pending JP2007502777A (ja) 2003-08-13 2004-08-13 腫瘍の処置のための白金錯体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006523414A Pending JP2007502777A (ja) 2003-08-13 2004-08-13 腫瘍の処置のための白金錯体

Country Status (8)

Country Link
US (6) US7566798B2 (https=)
EP (2) EP1664070B1 (https=)
JP (2) JP2007502301A (https=)
AT (2) ATE453653T1 (https=)
AU (3) AU2004270655B2 (https=)
CA (2) CA2535584A1 (https=)
DE (2) DE602004015811D1 (https=)
WO (2) WO2005023824A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019073560A (ja) * 2007-09-10 2019-05-16 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004270655B2 (en) 2003-08-13 2011-03-24 University Of South Florida Methods for inhibiting tumor cell proliferation
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
WO2005110477A2 (en) * 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2008519859A (ja) * 2004-11-10 2008-06-12 ユニバーシティー オブ サウス フロリダ 標的化した薬物送達のための白金錯体
WO2006065894A2 (en) * 2004-12-14 2006-06-22 University Of South Florida Methods for inhibiting stat3 signaling in immune cells
DE102004060934A1 (de) * 2004-12-17 2006-06-29 Wacker Chemie Ag Vernetzbare Polyorganosiloxanmassen
ATE488507T1 (de) * 2005-06-30 2010-12-15 Bionumerik Pharmaceuticals Inc Platinanaloga mit monoazolligand
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
WO2007047623A2 (en) * 2005-10-14 2007-04-26 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
US8026382B2 (en) 2007-05-18 2011-09-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
US8895610B1 (en) 2007-05-18 2014-11-25 Heldi Kay Platinum (IV) compounds targeting zinc finger domains
WO2008155727A1 (en) * 2007-06-18 2008-12-24 Platco Technologies (Proprietary) Limited Platinum (iv) complexes
WO2010067335A1 (en) 2008-12-12 2010-06-17 Platco Technologies (Proprietary) Limited Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
RU2491936C2 (ru) * 2011-07-11 2013-09-10 Борис Николаевич Анисимов Способ комплексного лечения больных паразитарными заболеваниями
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
CA2864481C (en) 2012-02-23 2020-07-14 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
BR112015023568B8 (pt) 2013-03-15 2024-01-02 Ann Mcfarland Sherri Composto à base de metal como composto fotodinâmico
AU2014248007B2 (en) 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
CN104230997B (zh) * 2013-06-13 2017-01-04 上海医药工业研究院 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用
WO2015013565A1 (en) * 2013-07-25 2015-01-29 Nemucore Medical Innovations, Inc. Platinum derivatives for hydrophobic formulations
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CA2958801A1 (en) 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
BR112017027285A2 (pt) 2015-06-19 2018-09-11 Syn Nat Products Entpr Llc ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
US10428099B2 (en) 2015-06-25 2019-10-01 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
MX2020005310A (es) 2017-11-21 2020-10-08 Medoncare Pharmaceutical Co Ltd Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
CN112175014B (zh) * 2020-10-10 2021-08-20 中国药科大学 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
WO2024063828A1 (en) 2022-09-21 2024-03-28 Oracle International Corporation Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849790A (en) * 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GR851932B (https=) * 1984-08-14 1985-12-13 Engelhard Corp
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
JPH01156989A (ja) * 1987-09-25 1989-06-20 Ss Pharmaceut Co Ltd 新規白金錯体
EP0328274B1 (en) 1988-02-02 1994-10-19 Johnson Matthey, Inc., Pt (IV) complexes
JP3520367B2 (ja) * 1994-12-22 2004-04-19 独立行政法人産業技術総合研究所 白金ニトロアンミン系錯体の製造方法
US6008395A (en) * 1995-02-28 1999-12-28 Kidani; Yoshinori Platinum (IV) complex, production process thereof and carcinostatic agent containing the same
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6145688A (en) * 1996-07-17 2000-11-14 Smith; James C. Closure device for containers
US5977393A (en) 1997-11-21 1999-11-02 California Institute Of Technology Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts
KR100246722B1 (ko) * 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
JP2002535247A (ja) * 1998-11-26 2002-10-22 ペンタファルム アクチェンゲゼルシャフト 輸送系複合体
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7034109B2 (en) * 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
AU2004270655B2 (en) 2003-08-13 2011-03-24 University Of South Florida Methods for inhibiting tumor cell proliferation
US20050288365A1 (en) 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
JP2008519859A (ja) 2004-11-10 2008-06-12 ユニバーシティー オブ サウス フロリダ 標的化した薬物送達のための白金錯体
WO2007006019A1 (en) 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849790A (en) * 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019073560A (ja) * 2007-09-10 2019-05-16 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
US10851075B2 (en) 2007-09-10 2020-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof

Also Published As

Publication number Publication date
US8598230B2 (en) 2013-12-03
US7759510B2 (en) 2010-07-20
US7566798B2 (en) 2009-07-28
US20100316704A1 (en) 2010-12-16
US20090285884A1 (en) 2009-11-19
AU2004264421A1 (en) 2005-02-24
WO2005023824A3 (en) 2005-06-09
US20100310645A1 (en) 2010-12-09
AU2004264421B2 (en) 2011-02-24
CA2535762A1 (en) 2005-03-17
US20050074502A1 (en) 2005-04-07
AU2011202386A1 (en) 2011-06-09
US20050080131A1 (en) 2005-04-14
WO2005016946A2 (en) 2005-02-24
DE602004024909D1 (de) 2010-02-11
WO2005023824A2 (en) 2005-03-17
US20080187992A1 (en) 2008-08-07
EP1675864A2 (en) 2006-07-05
WO2005016946A3 (en) 2005-09-29
JP2007502777A (ja) 2007-02-15
EP1664070A2 (en) 2006-06-07
US8247445B2 (en) 2012-08-21
CA2535584A1 (en) 2005-02-24
AU2004270655B2 (en) 2011-03-24
EP1664070B1 (en) 2008-08-13
US7763585B2 (en) 2010-07-27
ATE404574T1 (de) 2008-08-15
DE602004015811D1 (de) 2008-09-25
US7238372B2 (en) 2007-07-03
AU2004270655A1 (en) 2005-03-17
EP1675864B1 (en) 2009-12-30
ATE453653T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
JP2007502301A (ja) 腫瘍細胞の増殖を阻害するための方法
Levitzki Protein tyrosine kinase inhibitors as novel therapeutic agents
Huang Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications
Germain et al. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy
Li et al. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines
Niu et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Frank STAT3 as a central mediator of neoplastic cellular transformation
Lo et al. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators
Lo et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Xu et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
Huang et al. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells.
Blum et al. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics
Arthur et al. Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison
JP2000505441A (ja) キナゾリン化合物
Braun et al. Effects of the antifungal agent ciclopirox in HPV‐positive cancer cells: repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis
Alamdari-Palangi et al. MiRNA-7 enhances erlotinib sensitivity of glioblastoma cells by blocking the IRS-1 and IRS-2 expression
JP2008514726A (ja) ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
CN108774219B (zh) 抑制pd-1/pd-l1的小分子化合物及其用途
CN101503402A (zh) 2-苯胺嘧啶衍生物及其制备和用途
Bowman et al. Signal transducers and activators of transcription: Novel targets for anticancer therapeutics
Nagy et al. A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor
CA2904275A1 (en) Theramutein modulators
Li et al. Novel type of prodrug activation through a long-range O, N-acyl transfer: a case of water-soluble CREB inhibitor
US20120040457A1 (en) Small molecules that replace or agonize p53 function
Kuhn et al. Identification of AKT-regulated genes in inducible MERAkt cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120509